PL3073999T3 - Krystaliczna Postać I ibrutynibu - Google Patents
Krystaliczna Postać I ibrutynibuInfo
- Publication number
- PL3073999T3 PL3073999T3 PL14866302T PL14866302T PL3073999T3 PL 3073999 T3 PL3073999 T3 PL 3073999T3 PL 14866302 T PL14866302 T PL 14866302T PL 14866302 T PL14866302 T PL 14866302T PL 3073999 T3 PL3073999 T3 PL 3073999T3
- Authority
- PL
- Poland
- Prior art keywords
- ibrutinib
- crystalline form
- crystalline
- Prior art date
Links
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title 1
- 229960001507 ibrutinib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310616065.4A CN103694241A (zh) | 2013-11-27 | 2013-11-27 | Pci-32765的新晶型a及其制备方法 |
| CN201410542609.1A CN104327085B (zh) | 2013-11-27 | 2014-10-14 | Pci-32765的晶型a及其制备方法 |
| PCT/US2014/067586 WO2015081180A1 (en) | 2013-11-27 | 2014-11-26 | Crystalline form i of ibrutinib |
| EP14866302.4A EP3073999B1 (en) | 2013-11-27 | 2014-11-26 | Crystalline form i of ibrutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3073999T3 true PL3073999T3 (pl) | 2018-10-31 |
Family
ID=50355928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14866302T PL3073999T3 (pl) | 2013-11-27 | 2014-11-26 | Krystaliczna Postać I ibrutynibu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9751889B2 (enExample) |
| EP (1) | EP3073999B1 (enExample) |
| JP (1) | JP6483126B2 (enExample) |
| CN (2) | CN103694241A (enExample) |
| AU (1) | AU2014354728B2 (enExample) |
| CA (1) | CA2932059C (enExample) |
| DK (1) | DK3073999T3 (enExample) |
| ES (1) | ES2684094T3 (enExample) |
| HU (1) | HUE039718T2 (enExample) |
| IL (1) | IL245865B (enExample) |
| MX (1) | MX363265B (enExample) |
| PL (1) | PL3073999T3 (enExample) |
| PT (1) | PT3073999T (enExample) |
| WO (1) | WO2015081180A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| EP3122753A4 (en) | 2014-03-27 | 2017-11-29 | Perrigo Api Ltd. | Ibrutinib solid forms and production process therefor |
| CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| CA2958139A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
| CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
| US10477780B2 (en) * | 2015-02-13 | 2019-11-19 | Hgci, Inc. | Multiple cell tray with media plugs |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| MX2017011990A (es) * | 2015-03-20 | 2018-06-06 | Crystal Pharmatech Co Ltd | Metodo de preparacion de la forma a cristalina de pci-32765. |
| CN106153797B (zh) * | 2015-04-20 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种依鲁替尼及依鲁替尼制剂有关物质分析方法 |
| CN106153798B (zh) * | 2015-04-22 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途 |
| EP3337485B1 (en) | 2015-08-19 | 2021-03-17 | Sun Pharmaceutical Industries Ltd | Crystalline forms of ibrutinib |
| ITUB20155616A1 (it) * | 2015-11-16 | 2017-05-16 | Laboratorio Chimico Int S P A | Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina. |
| CN105294696A (zh) * | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| CN106905320A (zh) * | 2015-12-23 | 2017-06-30 | 杭州容立医药科技有限公司 | 一种适合药用的依鲁替尼及其制剂 |
| CN106995445B (zh) * | 2016-01-22 | 2021-08-03 | 山东新时代药业有限公司 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
| CN107286163A (zh) * | 2016-03-30 | 2017-10-24 | 上海星泰医药科技有限公司 | 一种依鲁替尼的新晶型及其制备方法 |
| CZ2016196A3 (cs) | 2016-04-06 | 2017-10-18 | Zentiva, K.S. | Pevné formy Ibrutinibu |
| CZ2016276A3 (cs) | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
| CN106117214A (zh) * | 2016-06-29 | 2016-11-16 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| CN106008529A (zh) * | 2016-08-08 | 2016-10-12 | 上海工程技术大学 | 一种依鲁替尼溶剂化物及其制备方法 |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
| WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | Novel forms of ibrutinib |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
| WO2019211870A1 (en) | 2018-05-02 | 2019-11-07 | Cipla Limited | Polymorphic forms of ibrutinib |
| BR112020022185A2 (pt) | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| EP3810590A1 (en) * | 2018-06-19 | 2021-04-28 | Merck Patent GmbH | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
| CN111138436A (zh) * | 2018-11-04 | 2020-05-12 | 鲁南制药集团股份有限公司 | 伊布替尼晶型a单晶及其制备方法 |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| CN113214261A (zh) * | 2020-01-21 | 2021-08-06 | 尚科生物医药（上海）有限公司 | 一种依鲁替尼晶型a的纯化方法 |
| TN2023000295A1 (en) | 2021-06-10 | 2025-07-02 | Hikma Pharmaceuticals Usa Inc | Oral dosage forms of ibrutinib |
| US11433072B1 (en) * | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
| CN117752664A (zh) * | 2023-12-13 | 2024-03-26 | 苏州晶云星空制药有限公司 | 一种包含伊布替尼晶型a的药物组合物及用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007107469A1 (en) * | 2006-03-20 | 2007-09-27 | F. Hoffmann-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| HK1206624A1 (en) | 2012-04-11 | 2016-01-15 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| CN103142601A (zh) * | 2013-03-13 | 2013-06-12 | 杭州雷索药业有限公司 | Pci-32765在制备抗血管生成类药物中的应用 |
-
2013
- 2013-11-27 CN CN201310616065.4A patent/CN103694241A/zh active Pending
-
2014
- 2014-10-14 CN CN201410542609.1A patent/CN104327085B/zh active Active
- 2014-11-26 WO PCT/US2014/067586 patent/WO2015081180A1/en not_active Ceased
- 2014-11-26 PT PT14866302T patent/PT3073999T/pt unknown
- 2014-11-26 AU AU2014354728A patent/AU2014354728B2/en active Active
- 2014-11-26 HU HUE14866302A patent/HUE039718T2/hu unknown
- 2014-11-26 EP EP14866302.4A patent/EP3073999B1/en active Active
- 2014-11-26 ES ES14866302.4T patent/ES2684094T3/es active Active
- 2014-11-26 MX MX2016006901A patent/MX363265B/es unknown
- 2014-11-26 US US15/100,247 patent/US9751889B2/en active Active
- 2014-11-26 JP JP2016535162A patent/JP6483126B2/ja active Active
- 2014-11-26 CA CA2932059A patent/CA2932059C/en active Active
- 2014-11-26 PL PL14866302T patent/PL3073999T3/pl unknown
- 2014-11-26 DK DK14866302.4T patent/DK3073999T3/en active
-
2016
- 2016-05-26 IL IL245865A patent/IL245865B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015081180A1 (en) | 2015-06-04 |
| EP3073999A1 (en) | 2016-10-05 |
| IL245865A0 (en) | 2016-07-31 |
| CN103694241A (zh) | 2014-04-02 |
| CN104327085B (zh) | 2016-08-24 |
| MX363265B (es) | 2019-03-19 |
| AU2014354728A1 (en) | 2016-06-16 |
| JP6483126B2 (ja) | 2019-03-13 |
| EP3073999B1 (en) | 2018-05-30 |
| PT3073999T (pt) | 2018-10-16 |
| MX2016006901A (es) | 2016-10-28 |
| CA2932059C (en) | 2019-07-02 |
| JP2016538314A (ja) | 2016-12-08 |
| CA2932059A1 (en) | 2015-06-04 |
| CN104327085A (zh) | 2015-02-04 |
| HUE039718T2 (hu) | 2019-02-28 |
| EP3073999A4 (en) | 2017-03-22 |
| US9751889B2 (en) | 2017-09-05 |
| IL245865B (en) | 2019-05-30 |
| AU2014354728B2 (en) | 2019-02-28 |
| US20170002009A1 (en) | 2017-01-05 |
| ES2684094T3 (es) | 2018-10-01 |
| DK3073999T3 (en) | 2018-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245865A0 (en) | Form i of crystalline ibrutinib | |
| ZA201507110B (en) | Crystal modifications of elobixibat | |
| GB201421334D0 (en) | Synthesis of aeizeolite | |
| EP2970081A4 (en) | SALTS OF TREPROSTINIL | |
| SI3077047T1 (sl) | Soli aramchola | |
| ZA201506156B (en) | Novel inhibitors | |
| PL3041945T3 (pl) | Wytwarzanie galakto-oligosacharydów | |
| ZA201604502B (en) | Use of benzimidazole-proline derivatives | |
| SMT202000499T1 (it) | Uso di inibitori-ccr3 | |
| IL240763A0 (en) | The halopyrazoles as thrombin inhibitors | |
| IL240171A0 (en) | A crystalline form of linaclotide | |
| DK2805823T4 (en) | Plastrør i mindst to lag | |
| GB201300324D0 (en) | Improvements to letter-plates | |
| GB201311130D0 (en) | Greensleeves I | |
| GB201300903D0 (en) | Crystalline Form | |
| TWM475821U (en) | Structure of mosquito-catch | |
| TWM475524U (en) | Structure of rivet-pulling | |
| PL3071575T3 (pl) | Wytwarzanie normorfinanów | |
| GB201301722D0 (en) | Quantifcation of bacteria | |
| AP2013007217A0 (en) | Conduction of electricity | |
| ZA201308183B (en) | Conduction of electricity | |
| PH32013001094S1 (en) | Toothbrush | |
| PH32013001096S1 (en) | Toothbrush | |
| AU354626S (en) | Toothbrush | |
| GB201304608D0 (en) | BenTime of Yisrael operable arrangement |